Literature DB >> 9755008

Reduced renal failure following thoracoabdominal aortic aneurysm repair by selective perfusion.

M J Jacobs1, L Eijsman, S A Meylaerts, R Balm, D A Legemate, P de Haan, C J Kalkman, B A de Mol.   

Abstract

OBJECTIVES: Renal failure and visceral ischemia are feared complications following thoracoabdominal aortic aneurysm (TAAA) repair, significantly contributing to mortality. This prospective study describes volume- and pressure-controlled perfusion of the renal and visceral arteries during TAAA surgery.
METHODS: In 73 consecutive patients (mean age 59 years), TAAA repair (27 type I, 28 type II, 8 type III and 10 type IV) was performed, using retrograde and selective organ perfusion. Sixteen patients had impaired renal function with blood creatinine higher than 100 mmol/l. During the thoracic part of the procedure, the mean distal aortic pressure was kept above 60 mm Hg by means of left-heart bypass. After opening the abdominal aorta, the renal and visceral arteries were individually perfused by means of perfusion catheters (9 French) in the first 33 patients (group I). Volume flow through each catheter was assessed with ultrasound flow meters and maintained at least at 60 ml/min. In addition to volume flow measurements, catheters with pressure sensors were used in the last 40 patients (group II), allowing pressure-controlled selective perfusion. The extent of the aneurysm was comparable in both groups.
RESULTS: Mean cross-clamp time for the thoracic part was 46 min, including proximal anastomosis and reattachment of intercostal arteries. Mean cross-clamp time for the abdominal part was 74 min, including re-implantation of intestinal and renal arteries and selective dacron grafts to the celiac-axis arteries (n = 5), superior mesenteric arteries (n = 8) and renal arteries (n = 25), through which the catheters guaranteed continuous perfusion during the time the anastomosis was performed. Urine output was uninterrupted in all patients, irrespective of cross-clamp time. In group I, one patient (3%) developed renal failure and three patients (9%) required temporary peritoneal dialysis. In group II, no patients developed renal failure and two patients (5%) required temporary peritoneal dialysis. Thirteen patients with pre-existing renal impairment did not deteriorate. No patients developed visceral ischemia or multiple-organ failure. Total in-hospital mortality was 6/73 (8%) and was related to cardiopulmonary complications.
CONCLUSIONS: Renal and visceral ischemia can be reduced significantly by continuous perfusion during cross-clamping in TAAA repair. Not only sufficient volume flow but also adequate arterial pressure appears to be essential in maintaining renal function.

Entities:  

Mesh:

Year:  1998        PMID: 9755008     DOI: 10.1016/s1010-7940(98)00164-x

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Open surgery for thoracic aortic disease.

Authors:  H J Safi; P R Taylor
Journal:  Heart       Date:  2003-08       Impact factor: 5.994

2.  Thoracoabdominal aortic aneurysm: diagnosis and management.

Authors:  Ramesh M Gowda; Ijaz A Khan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-04

3.  Perfusion techniques for renal protection during thoracoabdominal aortic surgery.

Authors:  Castigliano M Bhamidipati; Joseph S Coselli; Scott A LeMaire
Journal:  J Extra Corpor Technol       Date:  2012-03

4.  Visceral and renal protection in thoracoabdominal aortic surgery.

Authors:  Cuddalore Sadasivan Vijayashankar; George Jose Valooran
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-01-20

Review 5.  State-of the-art review on the renal and visceral protection during open thoracoabdominal aortic aneurysm repair.

Authors:  Karl Waked; Marc Schepens
Journal:  J Vis Surg       Date:  2018-02-08

6.  Effects of magnesium sulfate on supraceliac aortic unclamping in experimental dogs.

Authors:  Youngho Jang; Hyoung Yong Shin; Jin Mo Kim; Mi Young Lee; Dong Yoon Keum
Journal:  J Korean Med Sci       Date:  2005-08       Impact factor: 2.153

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.